论文部分内容阅读
为研究沐舒坦不同用药途径对新生儿肺炎的白细胞、降钙素原及超敏C反应蛋白的影响,本研究选择2013年3月至2015年3月期间我院收治的74例新生儿肺炎患儿,按照随机数表法将74例患儿分为观察组(37例)和对照组(37例)。对照组为30 m L的生理盐水与7.5 mg的沐舒坦相吸收后予以静脉滴注。观察组患儿在对照组的基础上将生理盐水4 m L与沐舒坦15 mg制成雾化液后进行雾化吸入。观察两组患儿治疗前后外周血白细胞(white blood cell,WBC)、降钙素原(procalcitonin,PCT)及超敏C反应蛋白(highsensitivity C-reactive protein,Hs-CRP)、血气指标变化,比较两组患儿的临床疗效及住院时间与临床症状消失时间。治疗后,观察组患儿总的有效率94.59%(35/37)明显高于对照组78.38%(29/37)(p<0.05);观察组患儿的WBC(10.24±2.03)×109/L、PCT(0.82±0.14)μg/L、及Hs-CRP(1.02±0.25)mg/L水平要比对照组低(p<0.05);观察组患儿的Pa CO2(4.52±0.76)k Pa低于对照组(5.71±0.89)k Pa,Pa O2(13.07±2.54)高于对照组(10.86±1.69)k Pa(p<0.05);观察组患儿的住院时间(6.03±1.02)d明显短于对照组(9.24±2.33)d,临床症状消失时间也短于对照组(p<0.05)。由此得出结论,静脉滴注与雾化吸入沐舒坦相结合的方式治疗新生儿肺炎,能明显降低患儿的WBC、PCT、及Hs-CRP水平,可改善患儿的血气指标,其疗效良好,不良反应少,安全性高,为新生儿肺炎治疗提供新的治疗思路。
In order to study the influence of different routes of mucosolvan on neutrophil, procalcitonin and hypersensitive C-reactive protein in neonatal pneumonia, 74 neonates with pneumonia in our hospital from March 2013 to March 2015 were selected Children, according to the random number table method, 74 cases were divided into observation group (37 cases) and control group (37 cases). The control group was treated with 30 mL saline and 7.5 mg mucosolvan and absorbed intravenously. The children in the observation group were treated with nebulization solution of saline 4 m L and ambroxol 15 mg on the basis of the control group, then atomized and inhaled. The changes of peripheral blood white blood cell (WBC), procalcitonin (PCT) and high-sensitivity C-reactive protein (Hs-CRP) and blood gas index were observed before and after treatment in both groups. Two groups of children with clinical efficacy and hospitalization time and clinical symptoms disappear time. After treatment, the total effective rate in the observation group was 94.59% (35/37), significantly higher than that in the control group (78.38%, 29/37) (p <0.05). The WBC in the observation group was 10.24 ± 2.03 × 109 / (P <0.05). The Pa CO2 (4.52 ± 0.76) kPa in the observation group was significantly lower than that in the control group (P <0.05) PaO2 (13.07 ± 2.54) was higher than that of the control group (10.86 ± 1.69) kPa (p <0.05). The length of stay in the observation group (6.03 ± 1.02) d was significantly lower than that of the control group (5.71 ± 0.89) k Pa Shorter than the control group (9.24 ± 2.33) d, the disappearance of clinical symptoms was also shorter than that of the control group (p <0.05). It was concluded that intravenous drip and inhalation of mucosolvan combined with the treatment of neonatal pneumonia can significantly reduce the children’s WBC, PCT, and Hs-CRP levels, can improve children’s blood gas index, its efficacy Good, less adverse reactions, high safety, new treatment for neonatal pneumonia to provide ideas.